ESR1 and neoplasm: It may further be suggested that the absence of an impact of staining for AGR2 on prognosis in ERα-negative patients may be related to the higher proliferation rate of their tumours and tendency to earlier metastasis, with other genes/gene products having a greater influence on patient outcome.